Clinical Focus
Business Focus
Spotlight
Subscribe
CE/CME
- Clinical Technology
- Adult Immunization
- Hepatology
- Pediatric Immunization
- Screening
- Psychiatry
- Allergy
- Women's Health
- Cardiology
- Pediatrics
- Dermatology
- Endocrinology
- Pain Management
- Gastroenterology
- Infectious Disease
- Obesity Medicine
- Rheumatology
- Nephrology
- Neurology
- Pulmonology
Exploring the First FDA-Approved Treatment to Delay T1D Onset: Mechanism of Action and Treatment Impact
Diabetes specialists from UCSD discuss teplizumab, the first FDA-approved drug for delaying onset of T1D, highlighting its benefits and mechanism of action.
EP: 1.Insights into the Burden of T1D: Genetic Links and Familial Considerations from UCSD Practitioners
EP: 2.The Vital Importance of Understanding and Addressing Training Gaps in Endocrinology Surrounding T1D Stages
EP: 3.The Crucial Impact of Early Intervention in Preventing T1D Stage Progression
EP: 4.Navigating T1D Risk Screening: Identifying Ideal Candidates, Understanding Autoantibodies, and Determining Timing for Rescreening
EP: 5.Understanding Autoantibody Screening Tests: Methods, Interpretation, and Analysis Practicalities
Now Viewing
EP: 6.Exploring the First FDA-Approved Treatment to Delay T1D Onset: Mechanism of Action and Treatment Impact
EP: 7.Exploring the TN-10 Teplizumab Clinical Trial: Patient Demographics and Efficacy Insights
EP: 8.Teplizumab Infusion Protocol: Clinical Processes and Strategies for Infusion Access Enhancement
EP: 9.Key Insights and Practical Tips: Wisdom from UCSD Practitioners for Effective T1D Management
Related Videos
Related Content
AI-Powered Diabetes Prevention Program Intervention Matches Human Coaching in Landmark Trial
October 27th 2025Article
After 1 year of coaching by the AI app or a DPP-associated coach, reductions in weight and HbA1c and increases in physical activity were equal, an outcome with great promise for scalability.
